IN8bio Announces Newly Granted Global Patents; Patents Cover Use Of The Combination Of Its Proprietary DeltEx DRI Platform With CAR-T And CPI's
Portfolio Pulse from Benzinga Newsdesk
IN8bio has been granted new global patents that expand the use of its DeltEx Drug Resistant Immunotherapy (DRI) platform to include Chimeric Antigen Receptor T-cell (CAR-T) and checkpoint inhibitors (CPIs). This broadens IN8bio's foundational intellectual property for its DeltEx DRI platform. The company now holds 19 total granted U.S. and international patents, with numerous pending patent applications.
September 19, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio's new patents could potentially strengthen its position in the market by expanding the use of its DeltEx DRI platform. This could lead to increased investor confidence in the company.
The new patents granted to IN8bio expand the use of its DeltEx DRI platform, potentially opening up new markets and applications for the company. This could lead to increased revenues and profitability in the future, which would likely be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100